quantusGL is a high-precision image diagnostic service for glaucoma risk screening, provided by Transmural Biotech based in Madrid, Spain. It analyzes and classifies images through quantitative texture analysis of retinal fundus images, providing a glaucoma risk probability within minutes. The website describes it as a non-invasive, fast, and easy-to-use web application suitable for general population screening, initial screening of at-risk patients, and medical waiting list prioritization.
The core product workflow is: users purchase a test online, receive an authorization code via email, visit a partner center for fundus imaging, and professionals complete the test to generate an electronic report. The test includes fundus image analysis and an electronic format report, but does not include doctor consultations or other supplementary examinations. For medical institutions, it is worth noting that it supports RESTful Web Services and is compatible with the HL7 FHIR protocol, providing the foundation for integration with medical information systems, electronic health records (EHR), or clinic systems. However, the website does not disclose API documentation, authentication mechanisms, SDKs, permission models, audit logs, or team collaboration features.
Pricing information is relatively clear: a single quantusGL trial is 75 EUR, tax included. Here, "trial" functions more like a single test purchase rather than a free trial. After purchase, users receive an authorization code and complete the examination at a partner clinic. The page does not provide information on institutional versions, subscriptions, bulk testing pricing, or insurance payments, nor does it specify payment methods.
Pros include a focused use case, where non-invasive testing lowers the screening barrier; fast report generation, suitable for immediate feedback in clinics; HL7 FHIR and REST support, which are friendly for medical SaaS integration; and transparent pricing, making it easy for individual users to estimate costs. The main drawbacks are that the website lacks key information such as detailed clinical validation data, regulatory certifications, privacy and security compliance, and data storage locations; testing relies on partner centers for fundus image capture, so it is not a fully online service; and doctor consultations and supplementary examinations incur additional costs.
It is more suitable for individuals needing glaucoma screening, ophthalmology/optometry institutions, primary care facilities, and clinics looking to perform risk triage. Access from China cannot be determined solely from the text, and payment methods as well as local partner clinic coverage are unspecified. If deployed in China, key considerations would include medical device registration, data compliance, hospital system integration, and local AI alternatives for fundus imaging.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on quantusgl.org official site.
quantusgl.org is an Spain SaaS Tools provider. TG4G tracks its product information, an overall rating of 5.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach quantusgl.org directly.